Results 141 to 150 of about 42,544 (264)
What should be the endpoints of oral therapy in HBeAg-positive versus HBeAg-negative patients with chronic hepatitis B [PDF]
Therapy with currently available oral nucleos(t) ide analogs (NA) in patients with chronic hepatitis B (CHB, HBeAg-positive or -negative) should ultimately aim at preventing progression to cirrhosis and hepatocellular carcinoma.
Hadziyannis, S.J., Vassilopoulos, D.
core
HBeAg differentially induces apoptosis of macrophages. [PDF]
(A) THP-1 macrophages stimulated with HSA, HBsAg, HBcAg, HBeAg together with control IgG or HBeAg in the presence of anti-HBeAg for three days were analyzed for their viability using the CCK8 assay.
Omid Akbari (390206) +9 more
core +1 more source
HBeAg 양성 만성 B형간염에서 precore 부위의 유전적 다양성 [PDF]
Dept. of Medicine/박사In patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), HBeAg seroconversion is an important clinical landmark during the natural course of CHB because it usually correlated with the sustained remission and ...
박준용
core
HBeAg clearance in chronic Hepatitis B: is it predictable? [PDF]
Introduction: Prediction of HBeAg loss is crucial for understanding the prognosis of chronic hepatitis B (CHB) and determining when to discontinue treatment.
İlgar, Tuba +5 more
core +1 more source
라미부딘유도 HBeAg 혈청전환과 자연적 혈청전환에서 혈청 HBV DNA치의 비교 [PDF]
PURPOSE: It has been suggested that the cumulative relapse rate in patients with spontaneous HBeAg seroconversion is usually lower than the rate in patients with lamivudine induced HBeAg seroconversion in Asians with chronic hepatitis B.
유, 준환
core
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Ting Chang +14 more
semanticscholar +1 more source
经相同肝实质细胞体积分摊的血清HBsAg水平与肝组织病理进展相关而与HBeAg状态无关
【目的】回顾性研究HBeAg阳性与HBeAg阴性慢性乙型病毒性肝炎之间,血清HBsAg的水平以及经相同肝实质细胞体积(肝细胞数量)分摊计算后血清HBsAg水平的异同。【方法】选取中山大学附属第三医院168例因病情需要而进行了肝穿刺活检及HBsAg定量检测的慢乙肝患者为研究对象。比较其HBeAg阳性与HBeAg阴性之间的血清HBsAg水平,以及经相同肝实质细胞体积(肝细胞数量)分摊计算后的血清HBsAg水平。【结果】血清HBsAg水平在HBeAg阳性和HBeAg阴性慢乙肝患者之间的差异有统计学意义(P=0.
doaj
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
G. Lau +14 more
semanticscholar +1 more source

